BPC-157 Frequently Asked Questions

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It has been extensively studied in preclinical research for its potential role in tissue healing, gut protection, and anti-inflammatory activity. ORYN BPC-157 is formulated at >99% purity in a precision-dosed pen system.

Research suggests BPC-157 may modulate multiple biological pathways including nitric oxide synthesis, growth factor expression (such as VEGF and EGF), and the FAK-paxillin signalling cascade. These mechanisms are thought to contribute to its observed effects on angiogenesis, tendon healing, and gastrointestinal protection in preclinical models. Note: these findings are from research studies and do not constitute medical claims.

BPC-157 is studied across a broad range of research applications including gastric ulcer healing, tendon and ligament repair, muscle injury recovery, bone fracture healing, neuroprotection, and inflammatory bowel conditions. It is one of the most versatile peptides in regenerative medicine research.

ORYN BPC-157 is delivered via a pre-mixed peptide pen system. Each pen contains 10 mg of BPC-157 in 3 mL, designed for subcutaneous injection. The pen system eliminates the need for manual reconstitution, reducing contamination risk and ensuring precise, consistent dosing throughout the 30-day protocol.

ORYN BPC-157 is manufactured to >99% purity in GMP-certified, ISO 7 cleanroom facilities. Every batch is verified by third-party HPLC and mass spectrometry testing. A Certificate of Analysis (CoA) is available for each batch, confirming identity, purity, and sterility.

BPC-157 pens should be stored refrigerated at 2-8°C (standard refrigerator temperature). Keep the pen away from direct light and do not freeze. When stored correctly, ORYN BPC-157 pens have a shelf life of 24 months. Once in use, the pen should remain refrigerated between doses.

BPC-157 is frequently studied alongside TB-500 in research protocols focused on tissue repair and recovery. The two peptides are thought to act through complementary mechanisms — BPC-157 primarily through the nitric oxide pathway and TB-500 through actin regulation. Researchers should design protocols based on published literature and consult relevant guidelines. This is not medical advice.

Each ORYN BPC-157 pen is designed for a 30-day dosing period. The pen contains 10 mg of BPC-157 in 3 mL of solution, with each click delivering a precise, pre-calibrated dose. The multi-dose design means one pen covers a full monthly research cycle.

Traditional BPC-157 vials require manual reconstitution with bacteriostatic water, syringe drawing, and careful dose calculation. ORYN's pen system is pre-mixed and ready to use, eliminating reconstitution errors, reducing contamination risk, and providing consistent dosing. The pen also features 0.22um filtration and gamma ray sterilisation for pharmaceutical-grade sterility.

BPC-157 is legal to purchase in the UK for research purposes. It is not approved as a medicine by the MHRA and is not intended for human therapeutic use. ORYN supplies BPC-157 strictly for laboratory and research applications in accordance with UK regulations.